Catheter Precision, INC 8-K filings

Catheter Precision, Inc. has filed a Certificate of Designation for its Series C-4 Convertible Preferred Stock, detailing its terms and rights.

Catheter Precision, Inc. announced the closing of its Series C-3 Convertible Preferred Stock sale, raising $3.47 million for working capital and general corporate purposes.

Catheter Precision, Inc. announced a private placement transaction where it purchased shares of Volato Group, Inc. for $1 million.

Catheter Precision announced a 200% year-over-year revenue increase to $432,000 for Q1 2026, driven by its medical device segment and the newly acquired aviation platform, Flyte, while also reducing its net loss.

Catheter Precision, Inc. announced the closing of its Series C-2 Convertible Preferred Stock offering, raising $3,470,000 in gross proceeds.

Catheter Precision shareholders approved the issuance of shares for multiple preferred stock series and a reverse stock split.

Catheter Precision, Inc. announced its 2025 financial results, reporting a 95% revenue increase and a strategic expansion into regional air mobility through the acquisition of Flyte, Inc.

Catheter Precision, Inc. has converted approximately $9.5 million in accrued royalty rights and future royalty obligations into newly designated Series J Convertible Preferred Stock, strengthening its balance sheet.

Catheter Precision, Inc. has entered into agreements to raise over $5.4 million through private placements and warrant exercises, while also acquiring a stake in an air-mobility company and planning to divest its legacy catheter business.

Catheter Precision, Inc. has amended its 8% Short Term Promissory Notes, totaling $1.5 million, extending their maturity dates to 2028 and 2029.

Catheter Precision, Inc. has terminated its At-Market-Offering Agreement with Ladenburg Thalmann & Co. Inc., having sold approximately $4.0 million of common stock.

Catheter Precision announced a 135% increase in Q3 2025 revenue, driven by international expansion of its LockeT and VIVO product lines.

Catheter Precision, Inc. stockholders approved an amendment to increase authorized common stock from 60 million to 500 million shares, among other proposals, at a Special Meeting held on October 10, 2025.

Catheter Precision, Inc. announced UK approval for its LockeT device and filed a legal opinion for a $1.07M stock offering.

Catheter Precision, Inc. has completed a 1-for-19 reverse stock split, reducing outstanding shares and adjusting equity instruments.

Catheter Precision, Inc. announced a 128% year-over-year revenue increase in Q2 2025, alongside key product advancements and clinical data, despite continued net losses and liquidity concerns.

Catheter Precision, Inc. stockholders approved a 1-for-19 reverse stock split to maintain NYSE American listing, alongside authorizations for significant share issuances related to warrants and convertible preferred stock.

Catheter Precision, a US-based medical device company, projects its highest LockeT sales to date in Q2 2025, driven by strong hospital demand and European market expansion, while also filing a legal opinion related to an 'at-the-market' common stock offering.

Catheter Precision, Inc. has issued a common stock purchase warrant to Ladenburg Thalmann & Co., Inc. as partial compensation for services rendered in connection with its recent PIPE financing, pending stockholder approval.

Catheter Precision, Inc. announced the discontinuation of employment for its Chief Commercial Officer, Marie-Claude Jacques, with CEO David Jenkins temporarily assuming the role.

Catheter Precision, Inc. has filed an 8-K detailing the significant dilution new investors will face from its ongoing at-the-market common stock offering, alongside updates to its negative net tangible book value.

Catheter Precision, Inc. has entered into an agreement with Ladenburg Thalmann & Co. Inc. to offer and sell up to $1.3 million of its common stock through an at-the-market offering.

Catheter Precision, Inc. announces a 74% increase in sales revenue for Q1 2025 and the acquisition of Cardionomics, Inc.'s assets.

Catheter Precision, Inc. has entered into a Securities Purchase Agreement to raise $1.5 million through the sale of Series B Convertible Preferred Stock and the issuance of Series L warrants.

Catheter Precision's subsidiary, Cardionomix, acquires assets related to a late-stage heart failure treatment in development, funding the acquisition through stock issuance and a promissory note.

Catheter Precision's subsidiary, Cardionomix, has entered into an asset purchase agreement to acquire assets related to a late-stage treatment for acute decompensated heart failure.

Catheter Precision's subsidiary, Cardionomix, is in negotiations to acquire assets related to a late-stage heart failure treatment from Cardionomic, Inc.'s assignee for the benefit of creditors.

Catheter Precision reports its financial results and operational progress for the year ending December 31, 2024, highlighting sales team restructuring, LockeT's market introduction, and progress in clinical studies.

Catheter Precision, Inc. has released its investor presentation dated March 2025, providing an overview of the company.

Catheter Precision, Inc. awarded incentive stock options to its CEO and CCO on January 29, 2025, under the company's 2023 Executive Incentive Plan.